Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q2 FY22 results · Jul–Sep 2021
Solara Active Pharma Sciences reported revenue from operations of ₹401.61 crore (up 1.0% from Q2 FY21) and net profit of ₹29.68 crore (down 47.6% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 401.61 | 397.56 | +1.0% | 405.57 | −1.0% |
| Other income | 3.31 | 6.12 | −45.9% | 5.91 | −44.0% |
| Total income | 404.92 | 403.68 | +0.3% | 411.48 | −1.6% |
| Profit before tax | 29.68 | 56.77 | −47.7% | 50.11 | −40.8% |
| Net profit for the period | 29.68 | 56.69 | −47.6% | 50.11 | −40.8% |
| Attributable to shareholders of the company | 29.71 | — | — | 50.07 | −40.7% |
| EPS, basic (₹) | 8.27 | 19.21 | −56.9% | 13.95 | −40.7% |
| Net margin (%) | 7.4 | 14.3 | 12.4 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 401.61 | 397.56 | +1.0% | 405.57 | −1.0% |
| Other income | 3.51 | 5.68 | −38.2% | 5.80 | −39.5% |
| Total income | 405.12 | 403.24 | +0.5% | 411.37 | −1.5% |
| Profit before tax | 30.23 | 55.94 | −46.0% | 50.56 | −40.2% |
| Net profit for the period | 30.23 | 55.94 | −46.0% | 50.56 | −40.2% |
| EPS, basic (₹) | 8.42 | 18.97 | −55.6% | 14.07 | −40.2% |
| Net margin (%) | 7.5 | 14.1 | 12.5 |
Consolidated
- Filed with BSE
- 12 Nov 2021, 14:45 IST
- Board meeting
- 11 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Nov 2021, 14:45 IST
- Board meeting
- 11 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE